A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

SU5416 (Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone; semaxanib) is a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR)2. A Phase I dose escalation study was performed. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used as a pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Donnell, A, Padhani, A, Hayes, C, Kakkar, A J, Leach, M, Trigo, J M, Scurr, M, Raynaud, F, Phillips, S, Aherne, W, Hardcastle, A, Workman, P, Hannah, A, Judson, I
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361651/
https://www.ncbi.nlm.nih.gov/pubmed/16222321
http://dx.doi.org/10.1038/sj.bjc.6602797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361651/
https://www.ncbi.nlm.nih.gov/pubmed/16222321
http://dx.doi.org/10.1038/sj.bjc.6602797

Ejemplares similares